2Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49 ). UK Prospective Diabetes Study (UKPDS) Group. JAMA, 1999, 281(21) : 2005 -12.
3Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of mefformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med, 1997, 103 (6) : 491 -7.
4Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008,359(15) : 1577 -89.
5Del Prato S, Felton AM, Munro N, et al. Improving glucose management : ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract, 2005, 59:1345 - 1355.
6Iozzo P, Hallsten K, Oikonen V, et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care, 2003, 26(7): 2069-74.
7Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab, 2006, 8(6) : 650 -60,.
8Weissman P, Goldstein BJ, Rosenstock J, et al Effeets of rosiglitazone added to submaximal doses of mefformin compared with dose escalation of mefformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin, 20051 21 i (12): 2029 -35.
9American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care, 2005, 28 (Suppl. 1 ):S4-S36.
10Hamann J.Garcia,Puig G,Paul J.et al. Comparison of Fixeddose Rosiglitazone/Mefformin Combination Therapy with Sulphonylurea Hus Mefformin in Overweight Individuals with Type 2 Diabetes Inadequately Controlled on Metformin Alone; Exp Clin Endocrinol Diabetes ,2008,116 ( 1 ) :6-13.
4Tassoni E,Conti R,Gallo G,et al.Aminocarnitine ureidic derivatives as inhibitors of carnitine palmitoyltransferase Ⅰ[J].Chem Med Chem,2010,5(5):666-669.
5Rufer AC,Thoma R,Benz J,et al.The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment[J].Structure,2006,14(4):713-723.
6Pinnick K,Neville M,Clark A,et al.Reversibility of metabolic and morphological changes associated with chronic exposure of pancreatic islet beta-cells to fatty acids[J].J Cell Biochem,2010,109(4):683-692.
7Gaidhu MP,Fediuc S,Ceddia RB.5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside-induced AMP-activated protein kinase phosphorylation inhibits basal and insulin-stimulated glucose uptake,lipid synthesis,and fatty acid oxidation in isolated rat adipocytes[J].J Biol Chem,2006,281(36):25956-25964.
8Prato S,Felton AM,Munro N,et al.Improving glucose management:ten steps to getmore patientswith type 2 diabetes to glycaemic goal[J].Int J Clin Pract,2005,59(11):1345-1355.
9Gu N,Kim BH,Rhim H,et al.Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets:a single-dose,randomized-sequence,open-label,two-period crossover study in healthy Korean volunteers[J].Clin Ther,2010,32(7):1408-1418.
10Yang W,Lu J,Weng J,et al.Prevalence of diabetes among men and women in China[J].N Engl J Med,2010,362(12):1090-1101.
